PA
QFIN icon

PharVision Advisers’s Qfin Holdings QFIN Stock Holding History

PharVision Advisers’s Portfolio QFIN Stock Details QFIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,547
Closed -$300K – 524
2025
Q4 		$300K Buy
15,547
+526
+4% +$11.8K 0.15% 273
2025
Q3 		$432K Buy
+15,021
New +$511K 0.24% 51

Other funds holding QFIN

AMH
Aspex Management (HK) Central, Hong Kong $6.9B AUM 28.37% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KFA
Krane Funds Advisors New York $2.44B AUM 12.99% 1-Year Est. Return
TC
Triata Capital Hong Kong $552M AUM 2.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GAMH
Greenwoods Asset Management (HK) Hong Kong $3.88B AUM 23.82% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

PharVision Advisers's QFIN Position: Q1 2026 in Review

PharVision Advisers sold out of Qfin Holdings (QFIN) in Q1 2026, closing a stake of 15,547 shares — an estimated $300K sold.

PharVision Advisers first reported a position in QFIN in Q3 2025 and held it in 2 quarters. The position peaked at $432K in Q3 2025. 177 funds tracked by Wall St. Rank hold QFIN as of Q1 2026.

  • PharVision Advisers reported no remaining Qfin Holdings position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 15,547 Qfin Holdings shares in Q1 2026, an estimated $300K.
  • PharVision Advisers first reported a position in Qfin Holdings in Q3 2025 and held it in 2 quarters.
  • PharVision Advisers's Qfin Holdings position peaked at $432K in Q3 2025.
  • 177 funds tracked by Wall St. Rank held Qfin Holdings as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.